EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Durable disease control after multimodal therapy and platinum-based chemotherapy rechallenge in advanced clear cell adenocarcinoma of the urethra with lymph node metastases: a case report

Akihiro Maeda, Shohei Tobu, Shuhei Kusano, Maki Kawasaki, Hiroaki Kakinoki, Mitsuru Noguchi

Frontiers in Urology · 22.06.2026 · 6

DOI: 10.3389/fruro.2026.1865730 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Urology, online erschienen am 22.06.2026. Verfasst von Akihiro Maeda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Saga University, Saga, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clear cell adenocarcinoma of the urethra (CCAU) is an extremely rare subtype of primary urethral carcinoma. Owing to its low incidence, the optimal treatment strategy for advanced or metastatic disease remains unclear. We report a case of advanced CCAU with lymph node metastases that achieved long-term disease control following multimodal therapy. Case presentation A 60-year-old woman presented with urinary retention and was diagnosed with primary urethral clear cell adenocarcinoma (cT4N2M0) with pelvic lymph node metastases. Neoadjuvant gemcitabine plus cisplatin (GC) chemotherapy achieved a partial response and was followed by robot-assisted radical cystourethrectomy combined with hysterectomy, vaginectomy, and pelvic lymph node dissection. Pathological examination revealed ypT4N2M0 disease with negative surgical margins. Adjuvant nivolumab was initiated but was discontinued because of immune-related hypothyroidism and nodal recurrence. Comprehensive genomic profiling demonstrated microsatellite stability, a low tumor mutational burden (1 mutation/Mb), and MET and MYC amplifications. As no actionable alterations were identified, GC chemotherapy was reintroduced and again achieved a partial response. The patient remains progression-free 32 months after diagnosis.

Conclusions

This case suggests that multimodal treatment combining radical surgery and platinum-based chemotherapy may contribute to durable disease control in selected patients with advanced CCAU and lymph node metastasis. Although genomic profiling did not directly guide therapy in this case, molecular characterization may provide a basis for future individualized treatment strategies for this rare malignancy.

Schlagwörter

Stichwörter der Autor:innen

case reportclear cell adenocarcinoma of the urethracomprehensive genomic profilingplatinum-based chemotherapyprimary urethral carcinoma

Autor:innen und Institutionen

  • Department of Urology, Faculty of Medicine, Saga University, Saga, Japan.

Zitieren

APA

Maeda, A., Tobu, S., Kusano, S., Kawasaki, M., Kakinoki, H., & Noguchi, M. (2026). Durable disease control after multimodal therapy and platinum-based chemotherapy rechallenge in advanced clear cell adenocarcinoma of the urethra with lymph node metastases: a case report. Frontiers in Urology, 6. https://doi.org/10.3389/fruro.2026.1865730

Vancouver

Maeda A, Tobu S, Kusano S, Kawasaki M, Kakinoki H, Noguchi M. Durable disease control after multimodal therapy and platinum-based chemotherapy rechallenge in advanced clear cell adenocarcinoma of the urethra with lymph node metastases: a case report. Frontiers in Urology. 2026;6. doi:10.3389/fruro.2026.1865730

BibTeX
@article{Maeda2026,
  author = {Maeda, Akihiro and Tobu, Shohei and Kusano, Shuhei and Kawasaki, Maki and Kakinoki, Hiroaki and Noguchi, Mitsuru},
  title = {Durable disease control after multimodal therapy and platinum-based chemotherapy rechallenge in advanced clear cell adenocarcinoma of the urethra with lymph node metastases: a case report},
  journal = {Frontiers in Urology},
  year = {2026},
  volume = {6},
  doi = {10.3389/fruro.2026.1865730}
}
Kostenlos starten →